Established in August 2019, Lingnuo Biopharmaceuticals independently developed proprietary technologies for extending the half-life of blood (long-acting) and transversing the blood-brain barrier. Utilizing these foundational technologies, the company has been working on orphan drugs for the treatment of severe, rare diseases, including complement-targeted antibodies and recombinant protein drugs. Their research and development pipeline includes First-in-class (FIC) products that focus on novel targets, mechanisms, and indications, as well as Best-in-class (BIC) products that optimize existing targets through platform technology enhancements.

Disease Domain	Count

Nervous System Diseases	3
Immune System Diseases	2
Endocrinology and Metabolic Disease	2

Top 5 Drug Type	Count

Enzyme	2
Recombinant protein	1
Single-domain antibody	1
Fusion protein	1
Antibody	1

Top 5 Target	Count

complement factor(Complement Factor)	2
ASA(Cerebroside-sulfatase)	1
VEGF x complement factor(Vascular endothelial growth factor x Complement Factor)	1
FcRn(IgG receptor FcRn large subunit p51)	1

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 03 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LIN-2007 ( FcRn )	Autoimmune Diseases More	Preclinical
LIN-2006 ( VEGF x complement factor )	dry age-related macular degeneration More	Preclinical
LIN-2102 ( complement factor )	Glomerulonephritis, IGA More	Preclinical
Recombinant arylsulfatase A(Linno Pharmaceuticals) ( ASA )	Leukodystrophy, Metachromatic More	Preclinical
LIN-2004	Leukodystrophy, Globoid Cell More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis